mRNA expression levels of certain genes have shown predictive value for the outcome of cytarabine-treated AML-patients. We hypothesized that genetic variants play a role in the regulation of the transcription of these genes. We studied leukoblasts from 82 patients with acute myeloid leukemia and observed various extent and frequency of differential allelic expression in the CDA, DCK, NT5C2, NT5C3, and TP53 genes. Our attempts to identify the causative regulatory single nucleotide polymorphisms by a bioinformatics approach did not succeed. However, our results indicate that genetic variations are at least in part responsible for the differences in overall expression levels of these genes.
The deoxynucleoside analog cytarabine (1-␤-D-arabinofuranosylcytosine) is a major component of the chemotherapeutic treatment of patients with acute myeloid leukemia (AML). The most important limitation for the use of deoxynucleoside analogs in the clinic is the presence of primary or acquired resistance. Several studies have identified clinically relevant mechanisms of resistance in patients with leukemia or other malignant diseases (Jordheim and Dumontet, 2007) . In particular, the mRNA expression level of several genes has been correlated to the outcome of the treatment with cytarabine or gemcitabine (2Ј-2Ј-difluorodeoxycytidine), another analog of deoxycytidine. In all of these studies, large variations in the expression levels of genes involved in cytarabine metabolism have been observed between patients, suggesting the presence of important regulatory mechanisms. In addition to differences in levels and activities of transcription factors and stability of mRNA, variations in the genomic sequence of the gene and its regulatory elements can influence the mRNA level. In fact, at least 25 to 35% of interindividual differences in gene expression are supposed to be caused by cis-acting variations (Pastinen and Hudson, 2004) .
When a heterozygous genetic variation induces a difference in mRNA expression level, the two corresponding alleles are expressed at different levels. This is called differential allelic expression (DAE) or allelic expression imbalance (Pastinen and Hudson, 2004) . Currently, DAE is studied in samples heterozygous for an exonic variation (exonic single nucleotide polymorphisms; cSNP) used as a marker to determine the relative amount of transcripts from the two alleles. This method allows the distinction between cis-and transacting effects because the cellular environment and mRNA extraction are exactly the same (Stamatoyannopoulos, 2004) . The cSNP used for the assessment of DAE is not necessarily responsible for the allelic expression imbalance, and additional investigations are needed to identify the functional regulatory variant (regulatory SNP; rSNP) or the underlying epigenetic modification (Milani et al., 2007) .
Specific mRNA expression levels can be used to predict the outcome of cancer patients treated with chemotherapy. Because genetic variants are partially responsible for variations in gene expression, these could potentially be used as more precise markers for this prediction (Stamatoyannopoulos, 2004; Abraham et al., 2006) . For AML, the use of reliable predictive markers would substantially increase the treatment success rate and the overall management of the cancer patients. Our main goal in this study was to investigate whether interindividual variations in mRNA expression levels of genes involved in the cellular response to cytarabine could, at least in part, be due to genetic polymorphisms. As a secondary goal, we tried to identify the rSNPs responsible for these differences. We focused on genes with a key role in the metabolism and mechanism of action of cytarabine and with strong evidence of clinical relevance. We chose the genes for the equilibrative nucleoside transporter 1, SLC29A1, deoxycytidine kinase, DCK, cytidine deaminase, CDA, cytosolic 5Ј-nucleotidases II and III, NT5C2 and NT5C3, and the tumor suppressor gene TP53. We used a method based on high-resolution melting-curve analysis to assess the DAE of these genes, determined their relative expression level, and tried to identify causative rSNPs in leukoblasts from 82 patients with AML.
Materials and Methods
Biological samples were obtained from 82 patients with AML at diagnosis before initiation of therapy, all followed in the Hematology Department of Edouard Herriot Hospital in Lyon, France. Approval was obtained from Lyon Protocol Review Board, and written informed consent was provided according to the Declaration of Helsinki. Mononuclear cells including leukemic cells were isolated by Ficoll-Hypaque sedimentation from peripheral blood (n ϭ 33) and bone marrow (n ϭ 49). Median percentages of blast cells in peripheral blood and in bone marrow were 61 (range, 13-99%) and 69% (range, 20 -95%), respectively.
Total RNA and genomic DNA were extracted with TRIzol Reagent (Invitrogen, Cergy Pontoise, France), and cDNA synthesis was performed with 1 g of total RNA using SuperScript III Reverse Transcriptase (Invitrogen) and oligo(dT) primers.
SNPs were genotyped by high-resolution melting-curve analysis of polymerase chain reaction (PCR) products in the presence of LCGreen Plusϩ (Idaho Technologies, Salt Lake City, Utah) (Reed and Wittwer, 2004) or a fluorescent probe (Crockett and Wittwer, 2001) , using a LightScanner Instrument (Idaho Technologies). All PCR primers and cycling conditions are described in supplemental tables.
DAE was assessed with the same technique as the genotyping, using cDNA and genomic DNA based on a previously described method (Ware et al., 2006) . All of the samples were amplified five times. Melting curves were analyzed with the HR-1 Instrument Analysis Software (Idaho Technologies), peak heights were measured manually, and the ratio of the two peaks corresponding to the two alleles was calculated for cDNA and genomic DNA. Allelic expression imbalance of each sample was calculated as the ratio (mean ratio for cDNA)/(mean ratio for gDNA). A sample was considered to have DAE if this ratio was Ͻ0.8 or Ͼ1.2 and if the difference between the mean ratios was statistically significant at p Ͻ 0.01 as calculated with the Student's t test. The linearity of the method for the assessment of DAE was validated using mix of genomic DNA from common and rare homozygous samples containing 20 to 80% of each allele. R 2 values were between 0.9918 and 0.9979 for CDA, NT5C2, NT5C3, and TP53. For NT5C3, PCR products of PCR1 were digested with PvuII to avoid interference with mRNA from pseudogene NT5C3P1 as described earlier (Marinaki et al., 2001) .
SNPs situated in putative transcription factor binding sites, or rSNPs, were identified in the region situated upstream of the start codon of genes of interest using the public databases RAVEN (http://www.cisreg.ca/cgi-bin/RAVEN/a), CONSITE (http://mordor.cgb.ki.se/cgi-bin/CONSITE/consite/), and TESS (http://www.cbil.upenn.edu/cgi-bin/tess/tess). Their evolutionary conservation was verified by comparative sequence analysis with mouse, dog, and cow using seqcom comparisons in FamilyRelations II (http://family.caltech.edu/) with a window size of 20 base pairs and a threshold of 0.8. Putative rSNPs for DCK and SLC29A1 were selected from the literature.
mRNA expression levels were determined by relative quantitative reverse transcription (RT)-PCR on an ABI PRISM 7900 sequence detection system (Applied Biosystems, Courtaboeuf, France) using GAPDH as internal standard and the comparative threshold cycle method as described in the user's guide. TaqMan gene expression assays were Hs00156401_m1 (CDA), Hs00176127_m1 (DCK), Hs00366992_m1 (NT5C2), Hs00826433_m1 (NT5C3), Hs00191940_m1 (SLC29A1), and Hs00153349_m1 (TP53).
The Student's t test was used for statistical analysis of DAE (differences in mean of ratios between cDNA and gDNA) and of the association between genotype and mRNA expression (differences in mean mRNA expression between genotype groups).
Results and Discussion
The DAE protocol can only be applied to samples that are heterozygous for a marker cSNP in the target gene. Genotyping CDA, DCK, NT5C2, NT5C3, and TP53 in our series of 82 patients revealed that 13 to 41 (15.9 -51.3%) were heterozygous for selected cSNPs with theoretically high frequency, and thereby suitable for the DAE experiments (Table 1) . For NT5C2, two highly frequent cSNPs were genotyped, but only rs3740387 in exon 18 was retained for DAEassessment. SLC29A1 was excluded from the analysis because only one heterozygote for the cSNP was found. This is consistent with the reported low frequencies of cSNPs in SLC29A1 in Europeans (Osato et al., 2003) . Statistically significant DAE was observed in 57.7, 50.0, 8.7, 38.5, and 16 .7% of positive samples for CDA, DCK, NT5C2, NT5C3, and TP53, respectively ( Fig. 1 ; Table 1 ). The extent of imbalanced allelic expression varied from 20% up to monoallelic expression of NT5C3 in four samples. The percentage of DAEpositive samples for each gene was not different between samples from peripheral blood and bone marrow. DAE has been reported to be tissue-dependent (Wilkins et al., 2007) , but here we studied the same cells (leukoblasts) in two different environments (peripheral blood and bone marrow). Detection of DAE provides strong evidence that cis-genetic variation is involved in the determination of the expression level of these genes. We observed DAE in leukoblasts that are the target cells for the cytarabine-based treatment of AML. Therefore, cis-regulation of these genes could have a direct impact on the efficiency of the chemotherapeutic drug used for treatment of AML. Because DAE was assessed in samples heterozygous for a marker cSNP only and the linkage disequilibrium with the causative SNP is unknown, it is difficult to estimate the rate of DAE in the whole population of 82 AML patients. The observed DAE could be due to genetic or epigenetic variants in transcription factor binding sites or by nonsense-mediated mRNA decay. We did not have biological material to study nonsense-mediated mRNA decay, but we continued our research on putative rSNPs.
Eighteen putative rSNPs in the 5Ј-region of our genes of interest were identified by bioinformatics tools or selected from the literature (Shi et al., 2004; Fitzgerald et al., 2006; Gilbert et al., 2006; Joerger et al., 2006; Myers et al., 2006; Sugiyama et al., 2007) . Compared with sequencing of large upstream regions of genes, this method allows screening of thousands of kb in silico to make a selection of potential rSNPs in either proximal promoters or more distant candidate enhancers (Wasserman and Sandelin, 2004) . The different databases identified various SNPs situated in potential transcription factor binding sites within the regulatory elements and for which the two alleles potentially did not have the same affinity for transcription factors (data not shown). Sequence conservation through mouse, dog, and cow was more or less constant. After genotyping of these SNPs, their comparison with the DAE status did not show any correlation (Table 1) . This result might be explained by the limited power of the study of some SNPs (few heterozygote samples) or reflect the fact that the studied SNPs do not intervene in the regulation of the expression of these genes. Functional rSNPs in our genes of interest can be as follows: SNPs that we did not chose to genotype; situated in sequences not reported on the publicly available databases; or situated elsewhere than upstream of the start codon. In addition, the analysis might have been complicated by the presence of several rSNPs in the same gene.
Median values (and ranges) for relative mRNA expression in leukoblasts from 67 patients were 8.1 (0 -215.3) for CDA, 12.6 (2.5-162.6) for DCK, 8.0 (0 -88.7) for NT5C2, 0.8 (0.1-6.0) for NT5C3, 1.0 (0 -18.2) for SLC29A1 (n ϭ 65), and 1.0 (0 -6.6) for TP53. This result confirmed our previous publications reporting large interindividual variations in gene expression between AML patients (reviewed in Jordheim and Dumontet, 2007) . If the role of the functional rSNP is important compared with other regulating parameters, genotypes should be correlated to the mRNA expression of the regulated gene, with heterozygous samples between the two groups of homozygotes.
Comparison between the genotype groups of cSNPs and rSNPs did 
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at ASPET Journals on July 7, 2017 dmd.aspetjournals.org not show statistically significant differences (Table 1) . However, trends were seen for rs2072671 in CDA [p ϭ 0.07 for comparison between heterozygote (19.16, n ϭ 36) and rare homozygous (5.75, n ϭ 11) samples] and for rs12261294 in NT5C2 [p ϭ 0.10 for comparison between the pool of common homozygous and heterozygote (13.23, n ϭ 56) samples and the rare homozygous (4.96, n ϭ 6) samples]. We did not observe higher expression for SLC29A1 in samples with C alleles for rs747199 as previously reported (Myers et al., 2006) . Lower promoter activity has been shown for T alleles of rs532545 in CDA, which is consistent with our mRNA data in TTsamples for this variant (Fitzgerald et al., 2006; Gilbert et al., 2006) . When subgroups of samples were compared for their correlation between genotypes and mRNA expression, statistically significant differences were observed in some cases. This was the case, for example, for rs4316067 in NT5C3 [p ϭ 0.005 for comparison between heterozygote (n ϭ 11) and rare homozygous (n ϭ 4) samples from peripheral blood only] and rs1042522 in TP53 [p ϭ 0.001 for comparison between common homozygous (n ϭ 22) and heterozygotes (n ϭ 14) samples from blood marrow only]. Comparison of gene expression levels between samples with or without DAE showed no differences (data not shown), thus eliminating low expression of the target gene as a bias of DAE assessment (Pastinen and Hudson, 2004) . This work provides proof that genes involved in the cellular response to cytarabine are subject to genetic or epigenetic regulation in leukemic blasts. The fact that a patient shows differential allelic expression in a cytarabine-related gene would not have an affect on FIG. 1. Allelic-specific expression of CDA (A), DCK (B), NT5C2 (C), NT5C3 (D), and TP53 (E) in leukoblasts from AML patients. All samples heterozygous for cSNPs in CDA (rs2072671), DCK (rs11544786), NT5C2 (rs10883841), NT5C3 (rs3750117), and TP53 (rs1042522) were assessed for DAE (5 replicates), and statistical significance was calculated using the Student's t test for comparison of the mean of the ratios of cDNA versus genomic DNA as explained under Materials and Methods. The y-axis shows the value of the ratio of mean cDNA ratios over mean gDNA ratios. Samples without DAE have a ratio of 1. Horizontal bars indicate the lower (0.8) and upper (1.2) limits of the Ϯ20% zone. The x-axis shows sample IDs. ‫,ء‬ samples with a ratio lower than 0.8 or higher than 1.2 and with p Ͻ 0.01 using the Student's t test; ‫,ءء‬ samples with monoallelic expression of NT5C3. BM, samples from blood marrow; PB, samples from peripheral blood.
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CDA_rs10916823_RP
GAGATTATTTACTCAGgCCC-F CDA_rs12095662_RP
CCTCACTTTGTTAAATCaCTTTTTCTCTC-F CDA_rs532545_FA
ATGCCTCCTGCCTcGGGATGC-F CDA_rs602950_RP
AGCTCCTCCCCtTGGGTGTGTC-F CDA_rs6690069_RP
TTGGGAAGGTCACACAcCATCTC-F CDA_rsE1_FB
CAGGAGGCCAAGaAGTCAGC-F DCK_rs-201_FA GCCGCcCCGCAGGCCCGC-F DCK_rs-243_RP TAGCTGCCCCTcGGCCCTCGC-F DCK_rs-360_RP TCTACCCCAAGCAGCCAGGCgCC-F DCK_rsE3_FA F-CAAACATATGCcTGTCTCAGTCGAA-P NT5C2b_rs7917650_FA CTTCAAAAAcAGAAGTGAAAC-F NT5C2b_rs12261294_FA ATCTTTCCgGATTGAAATTAC-F NT5C2_rsE18_FA F-CATGAcGAAGATGATGATGAAGAGGA-P NT5C3_rs13228639_RP AGCTcCGCCCCCACGAAGCC-F NT5C3_rsE6_FA
TAcTACGCTATTGAAGTTGATC-F NT5C4 rs4723239_RP
F-CAAACGTGAAACCTTtGACACTGC-P NT5C4_rs4316067_FA F-CGATAATAAAAATtTATTTACATAAGTG-P NT5C4_rs7778958_FA
CTGTATGTATCACAGCTTaTTCAC-F SLC29A1_rs747199_RP TCTGCTGTTGGCAcCTTAAC-F SLC29A1_rsE7_FA
GCCTGTGCTGTTAtCATTTTGAC-F TP53_rs17883670_FA
TTCCGATTGGGCcGCCGCATC-F TP53_rs17885803_RP
CACTTCTcCAGGCCTCTGCC-F TP53_rsR72P_FA
GGCTGCTCCCCgCGTGGC-F F : Fluoresceine ; P : Phosphate. SNP position is in bold and lowercase in probe sequence.
